Acquisition Growth Instem has expanded through multiple acquisitions including Strongtower, Samarind, PDS Life Sciences, and Leadscope, signaling ongoing integration needs and opportunities to consolidate platforms, migrate data, and accelerate cross-product adoption for customers.

Regulatory Demand Regulatory-driven needs such as updated nitrosamines guidance create sales opportunities for regulatory compliance modules, real-time updates, audit trails, and integrated toxicology workflows across R&D.

Pathology Synergy Partnerships like Pathcore and the centrus platform highlight a focus on digital pathology and toxicology workflows, presenting upsell opportunities for pathology analytics, data visualization, and seamless integrations with existing LIMS and cloud SaaS.

Mid-market Focus Instem's size and diversified SaaS portfolio align with mid-to-large life sciences firms and CROs seeking integrated discovery, toxicology, and regulatory solutions delivered on a scalable platform.

Cross Sell With a broad product suite spanning discovery, toxicology, and regulatory space, there are clear cross-sell and bundling opportunities across existing customers to drive broader platform adoption and faster value realization.